Abstract:Abstract Zika virus (ZIKV) is a mosquito-borne flavivirus that can cause Congenital Zika Syndrome (including microcephaly), Guillain-Barré syndrome, and other severe neurological disorders. Despite major efforts, there is no FDA-approved vaccine for ZIKV. Current efforts to develop ZIKV subunit vaccines have been exclusively focused on pre-membrane (prM) and envelope (E) proteins. However, the role of other viral proteins such as nonstructural protein 1 (NS1) in protection is poorly understood. Here, we developed two novel ZIKV vaccine candidates using non-segmented negative-sense RNA viruses (vesicular stomatitis virus, VSV; measles virus, MeV) as a vector. ZIKV prM-E-NS1 or prM-E gene was inserted into the attenuated VSV or MeV vector, and recombinant viruses expressing prM-E-NS1 or prM-E were recovered. The VSV- and MeV-based vaccine candidates were highly attenuated, induced strong ZIKV-specific antibody and T cell immune responses in animal models, and provided complete protection against ZIKV challenge in both immunocompetent and immunodeficient mice. Compared with vaccine candidates expressing only prM-E, ones with NS1 induced significantly higher levels of antibody and/or T cell responses and provided better protection against ZIKV infection, suggesting that NS1 plays a regulatory role in immune response and protection. In addition, we found that NS1, alone, is capable of conferring protection against ZIKV infection even though it did not induce neutralizing antibody. Our results demonstrated that prM-E-NS1 was superior to prM-E as a vaccine antigen. In summary, we have developed safe and highly efficacious ZIKV vaccine candidates, which are ready for pre-clinical trials in nonhuman primates and humans in the future.

Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model

A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission

Evaluation of Vertebrate-Specific Replication-Defective Zika Virus, a Novel Single-Cycle Arbovirus Vaccine, in a Mouse Model

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

A Single Injection of Human Neutralizing Antibody Protects Against Zika Virus Infection and Microcephaly in Developing Mouse Embryos.

Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice

Evaluation of an Engineered Zika Virus-Like Particle Vaccine Candidate in a Mosquito-Mouse Transmission Model

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Protocol for in utero injection to investigate Zika virus-related fetal microcephaly in mice

Novel Non-Segmented Negative-Sense Rna Virus-Based Vaccine Platforms For Zika Virus

Vaccine protection against Zika virus from Brazil

E90 subunit vaccine protects mice from Zika virus infection and microcephaly

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model

A Peptide-Based Viral Inactivator Inhibits Zika Virus Infection in Pregnant Mice and Fetuses.

An Attenuated Zika Virus Encoding Non-Glycosylated Envelope (E) and Non-Structural Protein 1 (NS1) Confers Complete Protection against Lethal Challenge in a Mouse Model

The Chimeric Chaoyang-Zika Vaccine Candidate Is Safe and Protective in Mice

Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus

Intra-amniotic Injection of Mouse Embryos